Rituximab-a B cell targeted therapy in systemic lupus erythematosus : where do we stand?
| Errataetall: |
CommentOn: Rheumatology (Oxford). 2022 May 5;61(5):1892-1899. - PMID 34240116 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 61(2022), 5 vom: 05. Mai, Seite 1752-1755 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Piantoni, Silvia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 25.05.2022 published: Print CommentOn: Rheumatology (Oxford). 2022 May 5;61(5):1892-1899. - PMID 34240116 Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/keac095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337232229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337232229 | ||
| 003 | DE-627 | ||
| 005 | 20231225233939.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/keac095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM337232229 | ||
| 035 | |a (NLM)35191468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Piantoni, Silvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab-a B cell targeted therapy in systemic lupus erythematosus |b where do we stand? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 25.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Rheumatology (Oxford). 2022 May 5;61(5):1892-1899. - PMID 34240116 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Murine-Derived |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 700 | 1 | |a Korsten, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 61(2022), 5 vom: 05. Mai, Seite 1752-1755 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2022 |g number:5 |g day:05 |g month:05 |g pages:1752-1755 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/keac095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2022 |e 5 |b 05 |c 05 |h 1752-1755 | ||